The discovery in the 1990s of BRCA1 (OMIM 113705) and BRCA2 (OMIM 600185) mutations in women susceptible to breast or ovarian cancer made targeted, individualized cancer preventive care possible.1 Germline BRCA mutations account for approximately 5% to 10% of breast cancer and 10% to 18% of ovarian cancer.2,3,4,5 Women who carry pathogenic variants of BRCA genes may undergo magnetic resonance imaging (MRI) with or without mammography screenings for breast cancer, which can lead to early diagnosis and timely treatment. This evidence concerns the gene BRCA1 and ovarian carcinoma.